|
Researchers
Help Shut Down Drug Counterfeiters
Wednesday, February 13, 2008
New techniques
developed to test suspected fake anti-malarials
Facundo
Fernandez, an assistant professor in Georgia Tech’s
School of Chemistry and Biochemistry, was part of an
international effort to halt the production of counterfeit
anti-malarial drugs.
|
Credit:
Georgia Tech / Gary Meek
Georgia Institute of
Technology researchers were part of a three-continent,
multi-organizational effort known as “Operation Jupiter”
that successfully identified and shut down manufacturers who were
flooding Southeast Asia with counterfeit – and ineffective
– anti-malarial drugs.
With 11 different
organizations, including the Centers for Disease Control and
Prevention (CDC), the World Health Organization (WHO), the
Wellcome Trust – and ultimately the international law
enforcement agency INTERPOL – the global effort provided
Chinese officials with enough information to shut down the drug
makers.
Beyond the human health cost of failing to
effectively treat hundreds of thousands of malaria cases, the
fake drugs could be fueling development of malarial strains that
may become resistant to the most sophisticated drug now available
to treat the disease: artesunate. That’s because
counterfeiters sometimes include small quantities of the real
drug in their fakes, possibly as part of an effort to fool simple
quality tests. By not killing the malaria parasites, the small
amount could facilitate development of drug resistance.
As
their part of the investigation, Georgia Tech researchers used
sensitive mass spectrometry techniques to analyze nearly 400
drug samples provided by public health authorities. They also
developed methods to speed up analysis, including an ionization
process that reduced the time required to test a drug sample from
half an hour to just a few seconds.
Activities aimed at
addressing the widespread problem of counterfeit anti-malarial
drugs were reported February 12th in the journal PLoS
Medicine. Georgia
Tech’s efforts to develop faster analytical techniques were
sponsored by the U.S. National Science Foundation, while the
sample analysis was supported by a small grant from WPRO/WHO.
Malaria kills more than a million people each year
worldwide, and is a risk for about 40 percent of the world’s
population. Most victims would survive – if they had access
to the proper drugs.
“About 50 percent of the
samples obtained from the field in Southeast Asia were fakes,”
said Facundo Fernandez, an analytical chemist and assistant
professor in Georgia Tech’s School of Chemistry and
Biochemistry. “They look very real, even down to the
hologram in the packaging. It’s very difficult to tell
which ones are the fakes and which ones are real.”
When
Fernandez began analysis of the drug samples, he assumed that
they would not include any real active ingredients. But his
graduate students Christina Hampton and Leonard Nyadong soon
discovered that the counterfeiters were making their fake
anti-malarials with a broad range of mostly expired
pharmaceuticals.
“We found old and ineffective
anti-malarials like chloroquine,” he said. “We found
antibiotics like erythromycin. We found all sorts of drugs that
basically have no effect on resistant malaria parasites.
Acetaminophen was one of the most common chemicals we found.”
Fernandez speculates that the makers chose certain
compounds, like acetaminophen, because they could temporarily
make patients feel better by lowering the fever associated with
malaria.
Mass spectrometry provides a very effective
means of identifying samples by determining their accurate
molecular weight. But the conventional analysis can be
time-consuming – especially in the preparation of samples.
Fernandez and his Georgia Tech group developed a faster
method that allows them to analyze hundreds of samples in a
single day. Their goal was to make mass spectrometry analyses
responsive within the time constraints that surveys in developing
countries and law enforcement agencies involved in
anti-counterfeiting tasks require.
“These are
methods that let you analyze a solid sample without any
significant preparation,” he explained. “You can take
a tablet, put it in front of the instrument with an ionization
source, and you get a quick snapshot of what’s in the
sample. It provides a very high throughput pipeline to identify
samples quickly.”
Ultimately, Fernandez hopes to
help develop high-accuracy instrumental tests that could be used
in the field to save the time and expense of shipping suspected
fakes to labs.
Beyond the mass spectrometry, the effort
also relied on analysis of pollen found in the drugs – a
discipline known as forensic palynology – which was done by
scientists in New Zealand who were part of Operation Jupiter. A
study of calcium carbonate isotopes in the compounds, together
with the pollen and active ingredients in the samples, pointed to
two main groups of samples originating in different geographic
regions of Asia.
“This is absolutely CSI –
the techniques they use on the television program really do work
in real life,” Fernandez said.
The Operation
Jupiter team provided enough information that Chinese authorities
were able to shut down the manufacturers, which were
sophisticated operations able to accurately mimic the packaging
and holographic seals of legitimate pharmaceutical companies.
Fernandez and his students remain involved in
anti-counterfeiting activities and hope to obtain additional
funding to continue supporting the efforts. They are now
investigating fake anti-malarials sold in Africa, analyzing
assortments of drugs sold in markets there, and studying other
faked drugs, such as tamiflu.
Fernandez got involved in
the project in 2003 because of a chance encounter with
Michael Green, a parasitic disease specialist at the CDC. He soon
began working with Green and with Paul Newton, a physician from
the University of Oxford in the United Kingdom who is based in
Laos.
Large pharmaceutical companies can afford to pursue
counterfeiting themselves, Fernandez noted, but in many cases,
drugs sold for use in developing nations come from small
companies that cannot afford private investigators and law firms
to go after the counterfeiters.
“The problem is not
over,” he cautioned. “There are more fakes and more
fake producers. But at least this is a beginning. Having an
opportunity to do some good in this area is very satisfying.”
Source:
Georgia Institute of Technology

|
Scientific
Frontline®
The
Comm Center
Space
Weather Alerts
Stellar
Nights®
The
E.A.R.®
World
News Report
Photo,
Sketches, & Video Gallery
|